A pooled data analysis of trials of the SGLT2 inhibitor empagliflozin in type 2 diabetes suggests it may lower the risk of kidney stones. However, this is early...
↧
Institute of environmental science and research - Could a Type 2 Diabetes Drug Tackle Kidney Stones?
↧